1. [Comparison of treatment planning by carbon ion radiotherapy and by intensity-modulated radiotherapy for prostatic adenocarcinoma].
- Author
-
Wang WH, Tsuji H, Ishikawa H, Tsujii H, Kamada T, Mizoe J, and Li YX
- Subjects
- Adenocarcinoma pathology, Aged, Femur Head radiation effects, Humans, Male, Prostatic Neoplasms pathology, Radiotherapy Dosage, Rectum radiation effects, Urinary Bladder radiation effects, Adenocarcinoma radiotherapy, Carbon Radioisotopes therapeutic use, Prostatic Neoplasms radiotherapy, Radiotherapy, Intensity-Modulated methods
- Abstract
Objective: To evaluate the potential benefit of carbon ion radiotherapy (C-ion RT) through comparison with photon intensity-modulated radiotherapy (IMRT) in dose distribution for prostatic adenocarcinoma., Methods: In randomly selected 5 patients, treatment planning of C-ion RT (4 coplanar beams) and IMRT (7 coplanar fields) were worked out by computer working station. In order to make a meaningful comparison, it was defined that the 95% isodose surface had to cover 100% of the PTV in each plan; all dose was given as normalized dose with the definition of the minimum dose of the PTV being equal to 95% of prescribed dose. Dose-volume histograms (DVHs) of the tumor and organ-at-risks (OARs) were calculated. Volume irradiated more than or equal to some specified doses, conformity index ( CI) , and inhomogeneity coefficient (IC) of each treatment plan was compared, respectively., Results: With C-ion RT, the mean irradiated volumes (in %) of the rectum were significantly smaller than that with IMRT except for 95% dose level, and C-ion RT could provide complete protection to the posterior rectal wall. In addition, C-ion RT could also remarkably reduce the dose to the bladder, femoral heads and non-target normal tissues at each dose level. Dose conformation and homogeneity in the target volume of C-ion RT were better than that in IMRT (mean CI50%, 3.36 vs. 5.04, mean CI95%, 1.20 vs. 1.46, mean IC, 0.03 vs. 0.12)., Conclusion: Compared with IMRT, C-ion RT can obtain better dose distribution, and may reduce tumor recurrence and radiation-induced complications in prostatic adenocarcinoma.
- Published
- 2006